SCHOLAR ROCK HLDG DL-,001 Logo
US80706P1030
A2JMQW
SRRK

SCHOLAR ROCK HLDG DL-,001

Forecast

The analysts' average price target is €64.99 (+48.11%). The median is €64.72 (+47.49%).

Buy
  13
Hold
  2
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Scholar Rock clarifies FDA requirements for ISEMBYLD, shares fall sharply

    Scholar Rock confirmed that the FDA requires post‑marketing conditions for ISEMBYLD, including a study on safety in pregnancy and 15‑day adverse‑event reporting for bone fractures. Management had previously (and incorrectly) stated that no such conditions existed. The stock then fell 6.4% to $51.85 and declined 9.7% on the week. Scholar Rock said it will carry out the requested studies and reporting in line with FDA requirements; analysts subsequently adjusted ratings and price targets. » More on de.investing.com


  • FDA grants approval for ISEMBYLD; Scholar Rock stock rises

    The FDA approved ISEMBYLD (apitegromab-mstn) as the first muscle-specific treatment for spinal muscular atrophy in adults and children aged two and older who are already receiving an SMN2-directed therapy. The news pushed Scholar Rock’s stock up about 9% pre-market to $60.45 and converts the company into a commercial biopharma company. Several analysts sharply raised price targets and reiterated buy ratings; apitegromab is projected to generate billions in sales by 2035. Scholar Rock reports roughly $492 million in cash and has independent fill-and-finish and manufacturing capabilities for the product launch. » More on de.investing.com


  • Scholar Rock receives FDA approval for Isembyld to treat SMA

    The FDA has approved Isembyld (Apitegromab‑mstn) for the treatment of spinal muscular atrophy in patients aged two and older. The approval is based on the phase‑3 SAPPHIRE study, in which patients receiving Isembyld in addition to standard therapy showed a significant improvement on the Hammersmith scale after one year; 34.2% achieved an increase of at least three points versus 13.5% with placebo. The US commercial launch has begun, the stock climbed more than 14% to an all‑time high, and Scholar Rock is shifting from a clinical biotech company to a commercial drugmaker. » More on deraktionaer.de


  • Scholar Rock prepares for FDA decision on apitegromab

    Weeks before the PDUFA date on September 30, 2026, Scholar Rock highlights late Phase III data on apitegromab as well as secured commercial production and go‑to‑market infrastructure. After an earlier Complete Response Letter over manufacturing issues, the company moved commercial fill‑finish production to an alternative site and says it has already produced commercial vials there. Management emphasizes statistically significant Phase III results, high treatment adherence, and prepared sales, nursing and patient‑support structures for the US, with plans for Europe and Japan. » More on de.investing.com


  • Scholar Rock nears approval for apitegromab

    At the Cantor Fitzgerald Global Healthcare Conference, Scholar Rock said the FDA has identified compliance with manufacturing requirements as the only remaining approval hurdle and that the company has since established a contractually committed alternative fill-and-finish facility. The crucial PDUFA date is September 30, 2026; management is holding intensive talks with the FDA about labeling and safety data. Scholar Rock has roughly $500 million in cash, sees worldwide market potential in the billions, and expects initial but manageable reimbursement and market-access hurdles during the first three to five quarters after launch. » More on de.investing.com

Financials

In the last quarter, SCHOLAR ROCK HLDG DL-,001 had revenue of €503.22K and net profit of -€94.68M

(EUR) September 2026
YoY
Revenue 503.22K -
Gross profit 496.16K 101.15%
Net profit -94.68M 8.69%
EBITDA -90.36M 5.55%

Fundamentals

Metric Value
Market capitalization
€5.35B
Number of shares
122M
52-week high/low
€56.30 - €35.27
Dividends No
Beta
0.62
P/E ratio
-14.95
PEG ratio
28.66
P/B ratio
37.77
P/S ratio
10,301.85

Company profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Name
SCHOLAR ROCK HLDG DL-,001
CEO
David L. Hallal
Headquarters Cambridge, ma
USA
Website
Sector
Consumer Staples
Industry
Food Products
IPO
05/25/2018
Employees 289

Ticker symbols

Exchange Symbol
NASDAQ
SRRK
Frankfurt
2QK.F
Düsseldorf
2QK.DU
München
2QK.MU
🍪

Parqet  uses cookies. Learn more